Significant Presence of Healthcare CROs in Chinais Escalating China Peptide Therapeutics Market

Published: Nov 2020

China's peptide therapeutics market will see a considerable growth of 6.8% during the forecast period. Since the last decade, China has emerged as a globally preferred destination for the outsourcing of drug research. The robust growth of China’s Contract Research (CRO) industry is encouraging the transition of outsourcing services at a large scale, thereby contributing to drug innovation. A significant portion of the research is being outsourced each year by the global innovator companies as part of R&D restructuring and cost-cutting initiative, especially in the analytical chemistry and peptide services. 

Browse the full report description of "China Peptide Therapeutics Market Size, Share & Trends Analysis Report, By Route of Administration (Oral and Parenteral), by Application (Cancer, Metabolic Disorder, Gastrointestinal Disorders, Central Nervous System Disorders, Respiratory Disorders, and Others), Forecast 2020-2026" at https://www.omrglobal.com/industry-reports/china-peptide-therapeutics-market

China has many domestic players offering outsourcing services to global companies in the peptide area. For instance, the Chinese Peptide Company (CPC) offers services to AstraZeneca Plc, Pfizer Inc., among other companies, around custom synthetic peptide, or API manufacturing. In addition, the companies across the country are partnering and collaborating with various global players to expand the peptide therapeutics market offerings. 

For instance, in January 2016, ChemPartner expanded its CRO service offerings into peptide chemistry with a significant investment in personnel and infrastructure, including the acquisitions of parallel peptide synthesis equipment. The initiative will enable the company to partner with other companies in therapeutic peptide drug discovery and partnership in other functional areas including biology, pharmacology, and Drug Metabolism and Pharmacokinetics (DMPK). 

Market Coverage

Report Elements

Details

Study Period

2019-2026

Base year

2019

Forecast period

2020-2026

Segments Covered

By Route of Administration and By Application

Key Companies Profiled

Eli Lilly & Co., Amgen Inc., AstraZeneca Plc, Astellas Inc., Pfizer Inc., and Teva Pharmaceuticals Co. Ltd.


Key questions addressed by the report

  • What is the market growth rate during the forecast period?
  • Which segment dominates the market in the base year?
  • Which segment will project the fastest growth in the market during the forecast period?
  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

China Peptide Therapeutics Market – Segmentation

By Route of Administration

  • Oral
  • Parenteral

By Application

  • Cancer
  • Metabolic Disorder
  • Gastrointestinal Disorders
  • Central Nervous System Disorders
  • Respiratory Disorders
  • Others (Kidney Disorder and Autoimmune Disorder)
To learn more about this report request a free sample copy @  https://www.omrglobal.com/request-sample/china-peptide-therapeutics-market